16 results about "Epilepticus status" patented technology

The present invention relates to the technical field of pharmaceutical chemistry, and provides a heterocyclic compound and a use thereof. The structure of the heterocyclic compound is as shown in formula II. The compound of the present invention has efficient sedative, hypnotic and / or anesthetic effects, can control the status epilepticus, further has an analgesic effect, and provides a new option for clinically preparing a drug having an analgesic effect, a drug having anesthetic, sedative and hypnotic effects and / or capable of controlling the status epilepticus, and a drug having anesthetic, sedative and hypnotic effects and / or capable of controlling the status epilepticus and also having the analgesic effect.

The present invention aims to provide novel compounds and their salts that are effective in the treatment, prevention, and / or diagnosis of seizures in diseases accompanied by epileptic seizures or convulsive seizures. [Solution] Formula I: TIFF2026050464000087.tif2685 [In the formula, each symbol is as described in the specification.] This relates to the pharmaceutical uses of the compounds and salts thereof shown in [reference]. These compounds and salts are useful for the treatment, prevention, and / or diagnosis of seizures in diseases involving epileptic or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures, and status epilepticus).

The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof:[in the formula, the symbols are as defined in the specification], which is useful for treating, preventing and / or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.

The disclosure provides an injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The injectable ganaxolone formulation optionally includes a surfactant and a pH modifier. The ganaxolone and sulfobutyl ether-β-cyclodextrin may be in an inclusion complex. The disclosure also provides a lyophilized powder of the ganaxolone / sulfobutyl ether-β-cyclodextrin formulation that may be reconstituted in water for injection. The disclosure provides a method of treating a patient having a seizure disorder, stroke, or traumatic brain injury, comprising administering an effective amount of the injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The disclosure also provides combination methods in which the injectable ganaxolone / sulfobutyl ether-β-cyclodextrin formulation is administered in combination with at least one additional active agent.

The present invention provides a novel heterocyclic compound represented by Formula [I] and a salt thereof:wherein the symbols are as defined in the specification, which is useful for treating, preventing and / or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.

To provide a new compound useful for treatment, prevention and / or diagnosis of seizure or the like in diseases accompanied by epileptic seizure or convulsive seizure (including multidrug-resistant seizure, intractable seizure, acute symptomatic seizure, febrile seizure and status epilepticus).SOLUTION: There are provided a compound represented by formula [I] and a salt thereof. Ring C is selected from pyridazine, pyrimidine, indole, pyrrolopyridine, indazole, pyrazolopyridine, imidazopyridine, imidazopyrazine, imidazopyridazine, triazolopyridine, pyrazolopyrimidine, imidazopyrimidine, triazolopyrimidine, isoquinoline, naphthyridine, quinazoline, quinoxaline, benzodioxole, oxazine, oxazepine, benzothiazole, and triazolopyridazine, with the proviso that pyrimidine-2, 4-dione and dihydropyrimidine-2, 4-dione are excluded.SELECTED DRAWING: None

Provided in the present invention are heterocyclic compounds, and a pharmaceutical composition and use thereof, belonging to the technical field of pharmaceutical chemistry. The series of heterocyclic compounds prepared by the present invention have effective sedative, hypnotic and / or anaesthetic effects, can control the status epilepticus, and also have an analgesic effect, thus providing a new option for clinical preparation of drugs having an analgesic effect, drugs having anaesthetic, sedative, or hypnotic effects and / or capable of controlling status epilepticus, and drugs having anaesthetic, sedative, or hypnotic effects and / or being capable of controlling status epilepticus and also having an analgesic effect.

The present invention relates to a unit dose composition comprising midazolam or a pharmaceutically acceptable salt thereof, cyclodextrin, and at least one matrix material, and to the use of the unit dose composition in pharmaceuticals and therapies, particularly in the treatment of febrile seizures, epileptic seizures, e.g., status epilepticus, fear, e.g., preoperative anxiety relief to alleviate fear, and / or agitation, e.g., preoperative agitation.

Provided in the present invention are a heterocyclic compound and the use thereof, belonging to the technical field of pharmaceutical chemistry. A series of heterocyclic compounds prepared in the present invention have highly efficient sedative, hypnotic, and / or anesthetic effects, can control status epilepticus, and also have analgesic effects, thus providing a new option for the clinical preparation of a drug having analgesic effects, a drug having anesthetic, sedative, and hypnotic effects and / or capable of controlling status epilepticus, and a drug having anesthetic, sedative, and hypnotic effects and / or capable of controlling status epilepticus which also has analgesic effects.

The present invention belongs to the technical field of medicine. Provided are a compound, and a preparation method therefor and the use thereof. The compound has a structure as shown in formula I. The compound of the present invention not only has efficient sedative, hypnotic and / or anesthetic effects, and the ability to control status epilepticus, but also exhibits an analgesic effect, and can reduce or avoid the use of opioid analgesics such as fentanyl, alfentanil, sufentanil or remifentanil in clinical application, thereby reducing the occurrence of adverse reactions such as circulatory depression, respiratory depression, urinary retention and pruritus caused by opioid analgesics.

Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid.

Provided for herein are prodrug compounds of benzimidazol-1,2-yl amide Kv7 activators. Particularly, the prodrug compounds have improved properties for stable formulation for treatment of Kv7 associated disorders, including seizure disorders. Also provided for are pharmaceutical compositions of said prodrug compounds and methods of treatment for seizure disorders including status epilepticus and others.

This invention provides the application of GSK484 in the preparation of anti-status epilepsy drugs, offering a new approach to the treatment of status epilepsy. The results of this invention show that GSK484 can significantly prolong the latency of Pilo-induced status epileptic seizures in mice, reduce the seizure severity in a Pilo-induced status epileptic model, and significantly reduce the duration of Pilo-induced status epileptic seizures. GSK484 can significantly inhibit neutrophil activation and extracellular trap formation in status epilepsy, and it does not affect mouse body weight. Therefore, GSK484 is an effective treatment for status epilepsy with good safety and minimal toxic side effects.

The invention provides a heterocyclic compound and application thereof, and belongs to the technical field of medicinal chemistry. The series of heterocyclic compounds prepared by the invention have efficient sedative, hypnotic and / or anesthetic effects, can control the state of epilepsy, also have an analgesic effect, and have great significance for clinically preparing drugs with the analgesic effect and drugs with anesthetic, sedative, hypnotic and / or capable of controlling the state of epilepsy. The invention provides a new choice for the medicine which has the effects of anesthesia, sedation and hypnosis and / or can control epilepsy persistence and also has an analgesic effect.

The present invention provides a method for treating various diseases with a novel heterocyclic compound represented by Formula [I] and a salt thereof:wherein the symbols are as defined in the specification, which is useful for treating, preventing and / or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.